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Abstract
Background: Chronic myelogenous leukemia (CML) results from the neoplastic transformation of a haematopoietic
stem cell. The hallmark genetic abnormality of CML is a chimeric BCR/ABL1 fusion gene resulting from the
Philadelphia chromosome rearrangement t(9;22)(q34;q11). Clinical and laboratory studies indicate that the BCR/ABL1
fusion protein is essential for initiation, maintenance and progression of CML, yet the event(s) driving the
transformation from chronic phase to blast phase are poorly understood.
Results: Here we report multiple genome aberrations in a collection of 78 CML and 14 control samples by
oligonucleotide array comparative genomic hybridization. We found a unique signature of genome deletions
within the immunoglobulin heavy chain (IGH) and T cell receptor regions (TCR), frequently accompanied by
concomitant loss of sequences within the short arm regions of chromosomes 7 and 9, including IKZF1, HOXA7,
CDKN2A/2B, MLLT3, IFNA/B, RNF38, PAX5, JMJD2C and PDCD1LG2 genes.
Conclusions: None of these genome losses were detected in any of the CML samples with myeloid
transformation, chronic phase or controls, indicating that their presence is obligatory for the development of a
malignant clone with a lymphoid phenotype. Notably, the coincidental deletions at IGH and TCR regions appear to
precede the loss of IKZF1 and/or p16 genes in CML indicating a possible involvement of RAG in these deletions.
Background
The BCR/ABL1 fusion, housed in the Philadelphia chro-
mosome and resulting from t(9;22)(q34;q11) or variants,
is the hallmark of chronic myeloid leukemia (CML) and
the most frequent recurrent genetic aberration in B lym-
phoid leukemia in adults [1,2]. The BCR/ABL1 fusion
gene encodes a constitutively active tyrosine kinase that
is necessary and thought sufficient to drive malignant
transformation. The natural history of the disease fol-
lows progression from a relatively benign chronic phase,
through accelerated phase into terminal blast crisis. This
course of events can be diverted or aborted by nearly
curative therapies, such as tyrosine kinase inhibitors,
transplantation and occasionally interferon [3] The sta-
ging of CML is based on clinical and pathologic fea-
tures, including bone marrow and peripheral blood
count, cytogenetic evolution and response to therapy
rather than biological criteria. Although at present the
molecular mechanisms that contribute to the develop-
ment of the blast crisis are largely unknown, it is well
established that the Ph bearing cells acquire additional
genetic changes during disease progression [3,4]. There
is evidence that the BCR/ABL1 fusion product not only
regulates numerous proteins involved in apoptosis, pro-
liferation and cell-cell interactions but also is a driving
force behind the acquisition of additional genomic
changes through regulation of the nucleotide excision/
mismatch repair systems and promoting unfaithful
restoration of double strand breaks [5]. This activity
could lead to the formation of mutations within the
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BCR/ABL1 kinase and accumulation of additional
genetic lesions, including point mutations, gene amplifi-
cations, genome loss and chromosome translocations
that are believed to drive the malignant process [6,7].
Mutations or abnormal expression of CDKN2A/2B, EVI-
1, RB, MYC and p53 among others have been reported
in CML (reviewed in Radich [3]). Gene expression pro-
filing studies have identified a relatively large number of
additional genes that are differentially expressed in
patients at advanced stages of the disease but no consis-
tent pattern has as yet been established (for review see
Guintas-Cardama, 2009 [4]). While recurrent genome
gains at a chromosomal level, such as +8, +19, +Ph and/
or iso17q, are associated with disease progression, the
occurrence of translocations is infrequent[8]. The identi-
fication of cryptic deletions at der(9)t(9;22) fuelled
expectations that submicroscopic lesions may mark dis-
ease evolution [9]. Indeed genome wide searches using
array comparative genomic hybridization (aCGH) by us
and others clearly demonstrated the accumulation of
genome imbalances in advanced stages of the disease
[10,11]. As the neoplastic transformation is occurring
early in a haematopoietic stem cell, the resulting blast
crisis (BC) in CML could be myeloid (BCM), lymphoid
(BCL), or indeed mixed (BCmix). Lymphoid BC occurs
in about a third of the CML patients [12] . Previous stu-
dies have shown that the BCL is characterized by the
loss of IKZF1 in the majority of the BCR/ABL1 positive
ALL cases and loss of CDKN2A/B in approximately half
of the CML/BCL patients [13]. These losses were rarely
present in non-BCL patients [14].
Here we report an analysis by oligonucleotide array
comparative genomic hybridization (aCGH) showing the
detection of universal deletions within both the immu-
noglobulin heavy chain and T cell receptor loci exclu-
sively present in lymphoid blast crisis CML. These
deletions are accompanied in a sub-set of cases by con-
comitant genome loss of regions within chromosomes 7
and 9, including the IKZF1 and CDKN2A genes, which
appear to be associated with variety of structural chro-
mosome changes - from cryptic interstitial deletions to
unbalanced rearrangements resulting in short arm or
whole chromosome loss.
Results
The fluorescence ratio (FR) standard deviation (SD) for
each of the 92 samples analysed with the 105 K array,
ranged from 0.057 - 0.187 with a median value of 0.092.
In a preliminary analysis of recurrent events, we
detected a set of 1,262 loci in the BC cohort with a FR
outside a threshold of ±4 SD that were seen in two adja-
cent probes in at least 3 samples. 410 loci corresponded
to known genes after correction for copy number varia-
tions (CNV) identified by Redon et al [15]. These genes
were found to be associated with Focal adhesion, MAPK
signalling and Cell cycle control and their distribution
across the genome is shown in Additional file 1: Figure
S1.
(i) Significance Analysis of Microarrays (SAM) identifies
concomitant genome losses associated with lymphoid
blast transformation
We chose SAM to carry out a 2-class analysis based on
myeloid and lymphoid BC CML for 74 samples - 60
CML and 14 control samples (Additional file 2: Table
S1). Altogether 435 loci were found with a FDR = 0. We
plotted the “expected” versus “actual” values of delta, the
metric that quantifies the difference between the two
classes and selected for further detailed consideration
the top 22 that displayed an enhanced value of delta
(Additional file 3: Figure S2). The heat map in Figure 1
illustrates the results of a hierarchical cluster analysis of
these probes. The complete set of the 435 significant
probes with reference to location, genome assignment
and scores are given in the supplementary data (Addi-
tional file 4: Table S2). Among the known genes covered
by these genome loci are IKZF1, HOXA7, CDKN2A/2B,
MLLT3, IFNA/B, RNF38, PAX5, JMJD2C and
PDCD1LG2.
The heat map (Figure 1) shows a dramatic demarca-
tion between lymphoid/mixed lineage and the remaining
samples where the green coloured columns indicate the
consistent genome loss. The top 22 most significant loci
are restricted to four chromosome regions, namely
7p12-14, 9p21-24, 14q11.2 and 14q32.33. Their deletion
status in the 10 BCL and 2 BCmix samples is shown in
Figure 2, where the probes are grouped by their geno-
mic location. None of these probes are consistently
deleted in any of the other samples studied. The probes
fall into two main groups. The primary group members,
highlighted in colour in Figure 2, are nearly always
deleted. These include probes covering the regions of
IGH, TCR and IKZF1 genes. The gains and losses for all
cases in the IGH region are summarised in Figure 3.
The locus at chr14:105.41 shows a 100% loss unique to
the BCL class (in blue) whereas the loci at chr14:105.61
and chr14:105.62 display either gains or losses typical of
CNVs. A region mapping to parts of the T-cell receptor
gamma chain complex region (TCRG) extending from
chr7:38.27 to chr7:38.32 on chromosome 7p14.1 is also
frequently deleted (Figure 4). There are five array probes
in this region, three of which are deleted in 11/12 sam-
ples (Figure 2). There are three probes in the 105 K
arrays covering the IKZF1 (Ikaros) gene, all of which are
deleted in 9/12 samples (Figure 2). The remaining
probes make up the second group, which represents the
full concomitant loss of loci within the 7p12-14, 9p13-
24.1 and 14q11.2 regions shared by 7 of the 12 BCL
samples (Figure 1 and Figure 2).
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(ii) Verification of the 105 K array results
Both FISH and aCGH on high-resolution custom oligo-
nucleotide arrays were used to verify of the 105 K array
results. FISH analysis of the TCR and IGH data was
considered inappropriate due to the small size of the
loci involved (2 - 50 k). All FISH tests for deletions of
IKZF1, CDKN2A, MLLT3, PAX5, JMJD2C and
PDCD1LG2 on cases where chromosome preparation
were available were positive. Furthermore, we identified
complex clonal heterogeneity as summarized in Figure
5. We applied aCGH at ~1 k resolution to the TCR,
IGH and IKZF1 loci on 40 samples, 10 from each group
of BCL, BCM, CP and controls (Figure 6 and Additional
File 5: Figure S3 and Additional file 6: Figure S4). The
copy number aberrations (CNA) identified by the 105 K
arrays were confirmed and in particular, the deletions of
TCR and IGH were shown to be remarkably consistent.
These deletions along with the IKZF1 loss were con-
firmed to be exclusively present in the BCL samples as
indicated by the whole genome study. Furthermore, in
case 163, a deletion of 119 Kb covering only exon 3 of
the IKZF1 region was revealed thus increasing the invol-
vement of this gene to 10/12 BCL samples (Figure 6).
A comparison of the location of the IGH probes found
as significant for the BCL samples with their
corresponding VDJ segments within the IGH@ locus
(IMGT database) is shown in Additional file 7: Figure S5.
The probe at chr14:105.41 is located between the IGHJ1P
and IGHD1-26 loci, while the chr14:105.48 probe - maps
between IGHV4-4 and IGHV(II)-1-1. This suggests that
the observed deletions in the BCL samples are likely to
result from an early VD joining that precedes any rear-
rangements the IGH@ region (Additional file 7: Figure
S5). Likewise, the probes found deleted within the TCRG
were located at the V and J segments and could reflect a
recurrent rearrangement. There are three probes in the
105 K array covering the TCR A/D region and they actu-
ally map within the TCRD sequences as follows: probe
chr14:21.98 is located between TRDD2 and TRDD3,
chr14:21.99 is located between TRDJ1 and TRDJ4 and
chr14:22.00 is located between TRDC and TRDV3 (Addi-
tional file 8: Figure S6).
(iii) G banding and molecular karyotype differ
While the array profile of the 12 samples with lym-
phoid/or mixed lineage immunophenotype share the
concomitant loss of loci harboured by chromosomes 7,
9 and 14, their karyotypes show no recurring pattern.
Aberrations ranged from a single Ph chromosome
abnormality (4/12) to multiple structural and numerical
aberrations of chromosomes 7 and 9 (3/12)(Additional
Figure 1 Heat map showing the 22 most signigicant probes for the lymphoid/myeloid dichotomy identified by sam analysis. The top
22 probes showing genome loss (in green) from a set of 435 probes identified by SAM analysis in a cohort of 60 CML and 14 control samples
as significant for lymphoid blast crisis (BCL). Data fall into three clusters: on the right are 8 BCL cases, on the left are 3 lymphoid together with 2
mixed lineage (BCmix) cases, while myeloid (BCM) and chronic phase (CP) samples make up the center cluster.
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file 9: Table S3). Only two samples (Case 156 and 200)
showed chromosome 14q32 aberrations. 4/12 samples
registered deletions of chromosomes 7 and 9 consistent
with their aCGH profiles. In the samples with segmental
deletions losses of the short arm varied in size from 5 to
20 Mb, whilst chromosomes 7 and/or 9 are monozygous
(Additional file 10: Figure S7). In cases 156, 163 (mixed
lineage) and 181, the IKZNF1 locus was diploid whilst
loci within TARP and TCRG at 7p14.1; TCRA at
14q11.2 and IGH at 14q32.33 were all deleted (Figure 2,
Additional file 11: Figure S8). Case 181, which by G
banding had a Ph chromosome as the sole karyotypic
abnormality, was shown by array to be monozygous for
the short arm of chromosome 7 with a break within
7p12.2 flanking IKZNF1 (which remains intact) together
with a loss of the 9pter-p13.1 including the loci from
the concomitant deletion (Additional file 11: Figure S8).
Discrepancies between the genome profile and the chro-
mosome findings were also recorded in Case 163 where
array analysis showed a genome gain of almost the
whole long arm of chromosome 17 and extra copy of an
~8 Mb region at 21q22.12 containing some of the Down
Syndrome Critical regions, ERG and ETS2 among other
known genes (Additional file 11: Figure S8).
(iv) Evolution of the concomitant genome loss in BCL
FISH analysis was employed to address the discrepancies
between the G banding and CGH data with main
emphasis on chromosomes 7 and 9. The FISH results
obtained in five cases, for which chromosome prepara-
tions were available, are summarized in Figure 5. Gen-
ome losses were confirmed in all cases studied as
illustrated by the results for case 164 (Figure 7). Multi-
ple Ph positive cell clones differing in the scope and
composition of the 7p/9p regional loss were identified
Figure 2 Unique genome loss in cml/bcl samples at address 105.41 within the IGH region. Graphic representation of CML/BCL samples
(vertical axis) showing imbalances in the IGH region at 14q32.33 for the probes on the 105 K Agilent arrays (genome address shown at the
bottom) with squares marking the FR values in excess of ±3 SD (calls), gains shown above and losses below with samples of chronic phase (in
green), myeloid blast crisis (red) and lymphoid blast crisis (blue). Note that losses dominate the lymphoid blast samples and that the probe at
105.41 Mbp is lost in all cases.
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in 4 of the 5 cases studied ranging in complexity (Addi-
tional file 10: Figure S7). Therefore it is unlikely that the
concomitant deletions in these cases result from a single
event. Instead, a spectrum of consecutive aberrations
probably leads to the formation of the concomitant loss.
Discussion
Although the frequency and size of the copy number
aberrations varied greatly, samples from both acceler-
ated and blast stage CML showed substantially larger
numbers of genome imbalances than chronic phase.
These aberration frequencies obtained at a resolution of
33 K by oligonucleotide aCGH are broadly in agreement
with earlier investigations of CML samples using BAC
[10,11] and SNP array CGH [14].
Altogether 435 loci were identified as significantly dif-
ferent in lymphoid and myeloid BC samples. All loci
were located on the short arms of chromosomes 7 & 9,
with the exception of 4 from chromosomes 14, 2 from
chromosome 2 and a single chromosome 22 probe.
Most of the probes mapped to known genes and a
number were in regions associated with immune
response. We show that deletion of certain regions
within TCR (alpha/delta and gamma) (11/12) and IGH
(12/12), are almost universal while being accompanied
by deletions within IKZF1 (10/12) and, to a lesser
extent, CDKN2A and sequences within several other
genes in the short arm regions of chromosomes 7 and 9
(7/12). These genome losses were not seen in any of 31
CP, 6 accelerated and 12 BCM samples or controls.
Furthermore, they were present in a BCL sample (Case
199) when DNA from the patient’s CP was used as
reference for the aCGH analysis, thus proving their sec-
ondary origin.
A recent genome wide single nucleotide polymorph-
ism (SNP) array analysis of Ph positive samples - 43
ALL (paediatrics and adults) and 23 CML (11 CP, 9
BCM and 3 BCL) [14] - revealed the presence of three
common deletions affecting the IKZF1, PAX5 and
CDKN2A loci. These deletions, confirmed by FISH and
qPCR, also detected in 2 out of 3 CML BCL samples,
were not always co-existent. How the reduced activity of
IKZF1 and PAX5 genes, that play a key role in regulat-
ing B lineage commitment, collaborates with BCR/ABL1
to induce Ph(+) ALL remains unclear [14,16]. The fre-
quency of the genome loss described by Mullighan et
al.,[14] in the Ph(+) ALL, is in overall agreement with
our findings in CML lymphoid blast crisis. In particular,
CDKN2A deletions are 53.5% in Ph(+)ALL . 58.3% in
CML/BCL and PAX5 loss is seen in 51.% of Ph(+)ALL
vs. 58.3% in CML/BCL, while deletions of IKZNF1 are
seen in 20 of 22 adults with Ph(+)ALL (90.9%) [14] and
our aCGH analysis at 1 K resolution detected loss in 10/
12 CML/BCL samples (83.3%). In contrast with the Ph
Figure 3 Concomitant losses in lymphoid blast crisis of cml: top 22 genome loci. The probe ID (Agilent), genome address, chromosome
location, gene content and distribution of the losses among the 12 Lymphoid BC in the studied cohort of 78 CML samples are shown.
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Figure 4 Unique genome loss in cml/bcl samples at address 38.27-32 within the tarp/tcrg region. Graphic representation of CML/BCL
samples (vertical axis) showing imbalances in the TARP & TCR gammaregion at 7p14.1 for the probes on the 105 K Agilent arrays (genome
address shown at the bottom) with squares marking the FR values in excess of ±3 SD (calls), gains shown above and losses below with samples
of chronic phase (in green), myeloid blast crisis (red) and lymphoid blast crisis (blue). Note that losses are present exclusively in the lymphoid
blast samples (arrow).
Figure 5 Clonality and evolution of the concomitant 7p/9p genome loss revealed by fish. Screening by FISH chromosome preparations
from CML patients using BAC and fosmid probes confirms the aCGH data and demonstrates the progression of the concomitant loss in
lymphoid blast crisis of CML.
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(+) ALL results, we found that the loss of IKZF1 always
precedes the deletions of CDKN2A and that losses of
RNF38 were always accompanied by loss of the 9p13-
p23.1 region that houses, among others, CDKN2A,
IFNA, RNF38, PAX5 and MLLT3. In addition, we
demonstrated by FISH the presence of clonal evolution
leading to the concomitant 7p/9p loss as seen in less
than half of patients (5/12 samples) (see typical aCGH
profiles in Additional file 10: Figure S7). Importantly,
the cell clone bearing the concomitant loss in the stu-
died cases was dominant and hence, detectable by
aCGH.
No imbalances of IGH and/or TCR loci were reported
in Ph(+) ALL study by Mullighan et al [14] either alone
or in combination with IKZF1, CDKN2A or PAX5. Sub-
stantial parts of the IGH and TCR regions are known to
show copy number variations (CNVs) in disease free
individuals http://projects.tcag.ca/variation, but whereas
CNVs are characterised by amplifications and deletions
of a specific locus within the sample population, we
found a set of probes in the IGH and TCR regions to be
universally deleted in exclusively lymphoid BC samples,
thus showing features typical of secondary genomic
aberrations. That they are not somatic aberrations is
illustrated by Case 199, where identical features emerged
when the BCL sample was hybridised against patient’s
DNA from the CP. These deletions characteristic of
lymphoid BC were also identified in the 2 samples with
mixed immunophenotype (Figure 1).
There are two possible explanations for the origin of
these deletions. Either they represent genome losses
associated with cross lineage rearrangements known to
occur in both ALL and AML, or they represent a bona
fide event with oncogenic potential. IGH/TCR rearran-
gement patterns are widely used to monitor minimal
residual disease (MDR) in a range of haematological
Figure 6 Mapping of IKZF1 (IKAROS) deletions at 1 kb resolution. Customized oligonucleotide aCGH results for IKZF1 (Ikaros) (exons 1-8,
highlighted) for 9 CML/BCL samples. Cases 156 & 163 (arrowed) are reported normal by 105 K arrays, while the rest are deleted. The genome
address is given on the left, where the large blue cross lines indicate the position of 105 K probes. Vertical lines represent results for each case -
the hair lines map losses at a resolution of ~1 Kb. The two data sets are consistent for all samples but one (case 163), where the high resolution
array revealed deletion of exon 3 only (red arrow), missed by 105 K array
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malignancies, the levels of which significantly correlate
with clinical outcome [17]. The immunophenotype data
for five of our 12 CML/BC samples that carry concomi-
tant 7p/9p loss (cases 184, 192, 193, 195 & 200, Addi-
tional file 12: Table S4) are consistent with early B cell
origin of the blast cells (TdT+, CD10+, CD19+, CD22+,
CD7 neg, so it could be that the recurrent loss of the
TCRG/D region in B cells with legitimate IGH rearran-
gements represents the lineage infidelity as reported pre-
viously in blast phase CML [18-21]. However, the
similarity of the deletions within both immunoglobulin
genes in BCL does not comply with the notion that IGH
and TCR configurations are unique (clonal by origin
and patient specific). The common deleted regions
could indicate a preferential VDJ rearrangement in the
clone that ultimately becomes dominant in the BCL
patients. Such preferential VDJ usage has been reported
before with a preference for the VH4 family segment in
about 35% of children with B-ALL [22]. In our case the
deletions in IGH and TCR loci possibly reflect the clonal
origin of the malignancy and the stage at which the
additional chromosomal aberrations that we observed
were initiated. Further work needs to be done to relate
these possibilities to the waterfall of changes that char-
acterise blast crisis.
So, how does the loss of a relatively small ~100 Kb
region from IGH and TCR contribute to the develop-
ment of the lymphoid blast transformation? RAG1 and
RAG2 (RAG) are the key components of the V(D)J
recombinase machinery that catalyses the somatic gene
rearrangements of antigen receptor genes during lym-
phocyte development. B cell progenitors undergo a
development program involving ordered IGH gene rear-
rangements conducted by the RAG enzyme system.
Recent evidence suggests that BCR/ABL1 induces
expression of activation-induced cytidine deaminase
(AID), found exclusively in early B cells. It participates
in the class switch recombination and has been shown
Figure 7 Case 195: fish interogates discrepanicies between karyotype and acgh results. Summary of molecular cytogenetic results for case
195: (a) G banding; (b) Array CGH (105 K Agilent) profile of chromosomes 7 and 9 with arrows pointing to sites of imbalances at the short arm
regions; Representative images of cells with FISH signals showing loss of one copy of (c) IKZF1 (green arrows), (d) PAX5 (yellow arrows), (e) p16
(red arrows) or both copies (green arrows), (f) PDCD1LG2 (red arrow) and (g) bi-allelic loss of MLLT3 (white arrows) thus confirming the aCGH
data.
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to lead to single strand breaks in IGH regions in Ph(+)
ALL [23]. Therefore, it would appear that the deregula-
tion of AID silencing by transcriptional or epigenetic
factors is the key event in compromising the V(D)J
recombination/RAG impairment. This could lead to the
TCR rearrangements in B cells, which have already
undergone IGH rearrangements and are expressing the
CD10, CD19 and CD22 antigens. Thus genome losses
identified in the BCL samples represent the consequence
of cross lineage rearrangement i.e. DJ joining occurring
in early B cells and aberrant incomplete recombination
in the TCR complex.
This view is supported by Mullighan et al [14] who
showed that the mechanism responsible for IKZF1 dele-
tions in Ph(+) ALL appears to involve aberrant RAG
mediated recombination as heptamer signal sequences
were found internal to the deletion breakpoints. Simi-
larly, CDKN2A loss was linked to RAG activity in lym-
phoid leukemia [24,25]. Furthermore, the impairment of
the RAG system in Ph positive cells could be a direct
consequence of the genetic damage caused by BCR/
ABL1 [5,23] either through inflicting direct damage via
reactive oxygen species or by compromised DNA repair
[4,7]. It is also possible that the reduced/abolished
expression of c-ABL [26] could further contribute to the
impaired V(D)J recombination [27]. In summary, a
chain of events initiated by BCR/ABL1 impairs the RAG
enzyme system. The compromised V(D)J recombinase
machinery is thus instrumental in creating, by means of
cross lineage rearrangements, clonal populations of
B-cell progenitors carrying IGH and TCR deletions.
Conclusions
We have observed a signature of deletions that is
uniquely present in our lymphoid samples. The top 22
most significant loci are restricted to four chromosome
regions, namely 7p12-14, 9p21-24, 14q11.2 and 14q32.33.
Their common appearance points at an event that is
orchestrating the cascade of aberrations leading to the
lymphoid BC. Given the high frequency of IGH and
TCRG loci deletions we speculate that the evolution into
lymphoid blast crisis is initiated by abnormal RAG
mediated NHEJ. It appears we are edging nearer to iden-
tifying the key aberrations responsible for blast transfor-
mation at least in a proportion of the CML patients.
Methods
Anonymous bone marrow (BM) archival samples
from chronic myeloid leukemia (CML) patients were
collected from 5 European hospitals. Altogether 92 sam-
ples were analysed of which 78 were from CML
patients, 31 in chronic phase, 10 in lymphoid blast crisis,
15 in myeloid blast crisis, 2 mixed lineage acute phase, 7
unclassified and 6 accelerated phase (Additional file 2:
Table S1). In addition, paired chronic and blast phase
samples were available for 7 patients, of which two were
classified as lymphoid blast crisis. As controls peripheral
blood mononuclear cell (PBMC) samples from 11
patients with cardiovascular disease (Approval from
Ethical Committee of St Anna Hospital in Sofia, Bul-
garia, No 54/28.02.2005) and 3 healthy individuals (Ethi-
cal approval by NRES at Royal Free Hospital and
Medical School, Ref 09/Ho720/97) were used. Cytoge-
netic data were available for 25 chronic and 27 blast cri-
sis patients (Additional File 4: Table S2). Presence of the
BCR/ABL1 fusion gene was confirmed in all samples by
qPCR and/or FISH (D-FISH probe, Vysis, USA). Immu-
nophenotyping data was available for 5 lymphoid blast
phase samples (Additional file 12: Table S4).
Array CGH and bioinformatics analysis
was performed with the Agilent 105 K oligonucleotide
arrays (Wilmington, DE, USA) following the manufac-
turer’s protocol. 500 ng genomic test DNA was extracted
from either peripheral blood or BM samples. Sex mis-
matched pooled DNA from PBMC of 6 - 8 disease free
individuals (Promega, UK) was used as reference in all but
the seven CML patients where the matched CP and BC
samples were hybridized against each other. Anonymous
DNA samples from PBMC of patients with cardiovascular
disease and healthy individuals were used as controls. The
dye swapped arrays were scanned at 5 μm resolution and
the resulting data analyzed using GenePix v6 software
http://www.moleculardynamics.com and MIDAS v2.19
http://www.tigr.org. We chose to analyse the results on
the basis of the fluorescence ratio (FR) calculated as the
normalized ratio of test to reference DNA, using the sim-
ple ratio rather than the logarithmic ratio. We used an
iterative method to calculate a standard deviation undis-
torted by outliers for the purposes of establishing a preli-
minary measure of aberration complexity threshold. The
emergence of high throughput technology such as micro-
arrays raises a fundamental statistical issue relating to test-
ing hundreds of hypotheses thus rendering the standard P
value meaningless [28]. Instead, the False Discovery Rate
(FDR) concept is becoming the key statistical assessment
tool replacing the P value. Tusher et al [29] described such
a method, Significance Analysis of Microarrays (SAM) and
the implementation due to Chu et al [30] has been incor-
porated by TIGR into their suite of ‘MeV’ routines. SAM
uses permutations of the repeated measurements to esti-
mate the FDR, the percentage of genes identified by
chance. We used SAM with a FRD = 0 for the supervised
analysis of the myeloid and lymphoid blast crisis, chronic
and control samples. Firstly, after removing data for the
sex chromosomes, we constructed a table defining the FR
for each locus and assigned classes e.g. blast crisis (BC),
chronic phase (CP) and Control; Lymphoid or Myeloid;
Male or Female. We chose a two class unpaired test using
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myeloid vs. lymphoid immunophenotype, and applied
SAM to ask if there were any probes that were uniquely
associated with either blast cell lineage. All genome
addresses are derived from build 35 (March 2006) of the
Human Genome.
A Customized oligonucleotide array CGH
comprising 8 × 15 k probe sets per slide was manufac-
tured by Agilent to our specification and used to verify
the losses identified by the standard whole genome 105
K array. Oligonucleotide probes from Agilent were
selected to cover regions at ~1 k intervals except from
genome locations where the presence of repetitive
sequences disallowed the design of reliable probes. The
arrays were scanned, features extracted and the data
analysed using an Agilent scanner and DNA Analytics
software. High-resolution graphics were generated using
Mathematica® http://www.wolfram.com.
FISH mapping
was carried out for further verification of the aCGH
results to identify the genome aberrations at a cellular
level using Bacterial Artificial Chromosomes (BAC)
clones obtained from the BACPAC Resources Center
(Children’s Hospital Oakland Research Institute, Oak-
land, CA, USA), the Sanger Centre (Cambridge, U) and
Invitrogen (Paisley, UK) following protocols in routine
use [31]. Where possible a minimum of 100 interphase
and 50 metaphase cells were screened with a dual col-
our dual FISH assay using BAC/fosmid probes selected
for optimal coverage of the regions of I KZF1,
CDKN2A, MLLT3, PAX5, PDCD1LG2 and JMJD2C
genes. The size of the FISH probes used was in the
range of 200 - 400 Kb.
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Additional file 8: Figure S6. The TCRG gene complex.
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27 samples from patients in blast crisis of cml.
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Additional file 10: Figure S7. Representative array cgh profiles of
concomitant loss of chromosomes 7 and 9 in cml lymphoid blast crisis.
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Additional file 11: Figure S8. Representative array cgh profiles of cml/
bcl cases with intact ikaros.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2164-11-
41-S11.PNG ]
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